Hims is the men’s brand of Hims and Hers Health, the only publicly traded company in this market. That matters less for the medicine than for the paperwork: it files annual reports and its numbers are audited, so what the business is doing is visible without having to reconstruct it.
In 2026 it moved almost entirely off compounded GLP-1 and onto branded, FDA-approved medication supplied through the manufacturers’ own self-pay programs — NovoCare for the Novo Nordisk products, LillyDirect for Eli Lilly’s. If you want the drug that was actually in the trials, this is one of the two places in our set that sells it.
The headline number is half the bill
Hims prices membership and medication as two separate subscriptions, and only the second one appears in the advertising.
The membership is $39 for the first month and $149 a month after that, for as long as you stay. It buys provider access and support, and their own page says plainly that it does not include or guarantee a prescription. The medication is billed on top: from $149 a month for the oral products, $199 for the Wegovy pen, $299 for the Zepbound vial or KwikPen.
So the real figures are $348 a month for branded semaglutide and $448 for branded tirzepatide, with a cheaper first month because of the $39 introductory membership. Anyone who walks away holding only the “from $149” number will be badly out.
The dose ladder nobody prints
There is a second gap, and it is the one worth asking about before you commit.
Hims names the doses on its weight-loss page — 0.25 mg for building tolerance, 2.4 mg for maintenance — without putting a price against any of them. The two other sellers of the same Novo product do discount the low rungs: Ro lists $349 across the range with $199 as a limited promotion, and NovoCare charges $349 ongoing after $199 for the first two fills.
That pattern makes it likely Hims has some structure at the low doses too. But likely is not published, and we quote what a provider prints rather than inferring what it probably does. Ask what your specific dose costs, and what it will cost when you titrate up.
Approved and compounded, sold side by side
The GLP-1 line is fully branded, but the rest of the catalog is not, and the page layout does not separate them.
The hair products are the clearest case: oral finasteride and topical minoxidil are FDA-approved drugs with decades of history, and the Hair Hybrids sprays and chewables are compounded, meaning no FDA review of safety, effectiveness or manufacturing. Both sit in the same grid of cards. The disclosure that says which is which is at the bottom of the page.
The same applies to testosterone. What is sold here is built on enclomiphene rather than the approved formats — cypionate injections, a topical gel, an approved oral — so if replacement therapy is what you came for, this is not it.
Here is every plan, what the price covers, and what it does not.
